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AbstrAct:
New biomarkers with improved accuracy could be helpful for monitoring disease in 
patients with Non-Hodgkin’s lymphomas (NHL). Towards this end, we have explored 
the feasibility of identifying the sequence of rearranged IgH genes using next-
generation sequencing, then using PCR to detect specific rearranged DNA fragments 
in patients’ plasma. By capturing and sequencing the IgH genomic regions (IgCap), 
we were able to detect and precisely determine the sequence of rearranged IgH loci 
in the tumors of three NHL patients. Moreover, circulating rearranged DNA fragments 
could be identified in the plasma of all three patients. Even in cases wherein tumor 
biopsies were unavailable, we were able to use the IgH capture approach to identify 
rearranged DNA loci in the plasma of 8 of 14 patients. IgCap may enable a more informed 
management of selected patients with NHL and other B-cell malignancies in the future.
IntroductIon
As cancer chemotherapeutics improve, the need 
for companion diagnostics to monitor the effects of such 
therapeutics becomes progressively more important.
[1] The ideal marker would be one that can be simply 
assessed without the need for repeat biopsies or exposure 
to irradiation, is absolutely specific for the presence of 
the tumor (to avoid false positives), is sensitive for the 
presence of disease, and is cost-effective.[2] Among the 
many new biomarkers being developed, those employing 
free, circulating somatically mutated DNA sequences 
in the plasma are particularly attractive because they 
can in theory meet all these criteria.[3, 4] In particular, 
mutations are exquisitely tumor-specific because they are 
not found in any collection of normal cells in the patient, 
and thereby have advantages over markers that are simply 
associated with tumors, such as CEA or PSA.[5] 
Circulating mutant DNA has been found in a variety 
of solid tumors and initial studies have shown them to 
provide sensitivity and specificity comparable or superior 
to conventional disease indicators.[6] In liquid tumors 
such as leukemias, consistently fused genes like BCR-
ABL provide extraordinarily useful markers for following 
patients during their treatment.[7] In leukemia patients, 
rearrangements can be accessed in the blood or bone 
marrow by virtue of the fact that any residual cancer 
cells will reside in these compartments.[8] In tumors 
such as lymphomas, however, circulating cells are not 
consistently found in patients’ blood or marrow. Based 
on the above-cited results on solid tumors, however, we 
hypothesized that somatically rearranged DNA templates 
from lymphomas might be found in the cell-free fraction 
of blood, i.e., the plasma.
To test this hypothesis, and to develop a generally 
applicable tool for companion diagnostics of B-cell 
lymphomas,  it  was  first  necessary  to  identify  aberrant 
DNA  sequences  that  could  be  identified  in  lymphoma 
patients.  Though  no  specific  point  mutations  or 
oncogene rearrangements are found in lymphomas in 
general, virtually all lymphomas harbor rearrangements 
in their immunoglobulin (Ig) genes.[9] Clever assays Oncotarget 2011; 2:  178 - 185 179 www.impactjournals.com/oncotarget
that reveal such rearrangements have been described, 
particularly those employing multiplex PCR to identify 
clonal rearrangements upon electrophoresis through an 
increase in the signal of a fragment “spike” representing 
the rearrangement.[10] Though such assays are clinically 
useful in many situations, the “spikes” representing clonal 
rearrangements can be difficult to detect, either because 
of  inefficient  primer  annealing  to  the  hypermutated 
sequences in rearranged Ig genes. More importantly, such 
assays cannot provide optimal sensitivity, as the tumor-
specific spikes are overlaid on a background of normal 
Ig  rearrangements.  The  tumor-specific  rearrangements 
can therefore only be observed if their abundance 
is  significantly  greater  than  the  aggregate  level  of 
rearrangements from normal B cells. Nonetheless, the 
appearance of such spikes in plasma correlates with 
the presence of lymphoma and persistence of such 
spikes following chemotherapy seems to portend a poor 
prognosis. To enhance the specificity of this plasma-based 
approach, we set out to use a capture-and-sequence method 
to more specifically identify rearrangements of IgH genes 
at the sequence level then to use this information to detect 
the same rearrangements in the plasma of NHL patients.
results
strategy
We chose to identify the rearrangements in DNA 
rather than RNA because RNA of adequate quality is 
not available in many clinical situations while DNA can 
be readily obtained even from archival samples. IgCap 
involves three steps: (i) the tumor DNA is first randomly 
sheared and ligated to adapters that allow their subsequent 
amplification by PCR; (ii) fragments containing IgH genes 
are captured on a solid support containing the sequences 
of interest [11]; and (iii) the captured DNA is amplified 
by conventional PCR, producing an IgCap library, and 
the ends of the captured DNA fragments are subjected to 
massively parallel sequencing.
The sequence information obtained is then processed 
in silico to identify rearranged sequences. Note that IgCap 
captures  all  fragments  containing  relevant  IgH  gene 
sequences, not simply the rearranged fragments. Moreover, 
the actual targets of this analysis, i.e., the rearranged loci, 
are nearly always mutated, both within the exons and at 
Table 1:  Sequencing summary  
Patient ID Total tags
Bases 
Sequenced
Tags 
matched 
uniquely to 
human 
genome
Bases 
matched to 
genome
Tags 
matched 
to the Ig
region
Tags 
matched to 
the Ig
coding 
sequences
Bases 
matched to 
the Igregion
Average 
coverage 
of the Ig
region
Target bases 
with more 
than 10 reads 
(number)
Target 
bases 
with 
more 
than 10 
reads (%)
Patient 1 18,889,095  944,454,750 7,359,299 367,964,950 214,548 88,916 10,727,400 251 14437 61%
Patient 2 3,183,730  159,186,500 1,109,460 55,473,000 166,626 97,334 8,331,300 275 13826 59%
Patient 3 11,265,224  563,261,200 6,077,027 303,851,350 164,494 78,858 8,224,700 223 14373 61%
Patient 4 17,306,516  865,325,800 5,053,458 252,672,900 320,330 162,534 16,016,500 459 14401 61%
Patient 5 11,149,375  557,468,750 4,385,951 219,297,550 114,142 52,816 5,707,100 149 13912 59%
Patient 6 4,166,839  208,341,950 2,351,275 117,563,750 119,952 59,362 5,997,600 168 14588 62%
Patient 7 3,875,106  193,755,300 2,405,508 120,275,400 125,808 64,365 6,290,400 182 14611 62%
Patient 8 9,741,614  487,080,700 6,221,945 311,097,250 131,132 57,886 6,556,600 163 14726 62%
Patient 9 2,673,399  133,669,950 1,391,649 69,582,450 36,284 19,443 1,814,200 55 13541 57%
Patient 10 16,909,387  845,469,350 10,206,055 510,302,750 156,254 70,047 7,812,700 198 14656 62%
Patient 11 15,218,254  760,912,700 7,460,806 373,040,300 450,949 268,217 22,547,450 757 15888 67%
Patient 12 9,693,373  484,668,650 5,592,951 279,647,550 145,140 64,939 7,257,000 183 14526 62%
Patient 13 3,344,057  167,202,850 1,982,627 99,131,350 53,919 31,062 2,695,950 88 13644 58%
Patient 14 16,818,309  840,915,450 6,464,306 323,215,300 334,392 155,854 16,719,600 440 14642 62%
Patient 15 22,785,641  1,139,282,050 12,265,838 613,291,900 830,469 609,774 41,523,450 1721 16851 95%
Patient 16 19,547,977  977,398,850 11,370,485 568,524,250 789,493 586,682 39,474,650 1656 16866 95%
Patient 17 21,925,769  1,096,288,450 12,059,079 602,953,950 701,194 503,556 35,059,700 1421 16837 95%Oncotarget 2011; 2:  178 - 185 180 www.impactjournals.com/oncotarget
the borders of the rearranged exons. Both these features 
make  the  identification  of  rearrangements  challenging, 
particularly when only a relatively small number of bases 
from each fragment are determined, as with the Illumina 
instrument. However, we were able to develop algorithms 
that could identify rearranged IgH genes on the basis of 
several features that distinguish them from unrearranged 
genes. In brief, we developed two algorithms, one that 
could be used for analysis of one end of a tag and the 
other for both ends in paired-end reads. The first algorithm 
(called  the  “CTGGGG-algorithm)  identified  “seed” 
fragments that contained a 6 nt sequence which was 
identical to, or differed at one position, from a conserved 
sequence present in all J genes (CTGGGG). The second 
algorithm (called the “paired-end algorithm”), used 
paired-end reads to identify two sets of seed fragments. 
The first set included fragments related to normal V, D or 
J regions but whose ends represented sequences separated 
by >10000 bp in unrearranged DNA and in the expected 
orientation. The second set included fragments in which 
one of the two ends was related to normal V regions and 
the other end included specific sequences within J or D 
regions.  The  J-specific  sequence  was  CTGGGCCA, 
while the D-specific sequences included the middle five 
bases of each of the D regions. In both algorithms, seed 
fragments were extended to include larger regions of V, 
D or J by performing homology searches among the other 
fragments in the sequenced IgCap library. 
To determine the sensitivity of these algorithms 
for identifying rearranged IgH genes, we tested it on 89 
known rearrangements recorded in the IMGT/LIGM-DB 
database (Supplementary Table 1). We randomly cleaved 
~100,00 bases spanning each rearrangement in silico to 
generate a virtual library of overlapping fragments of 
100 bp that mimicked the size of the DNA fragments 
actually used to make IgCap libraries. Each library was 
then analyzed using the two algorithms. The combination 
of the alogorithms resulted in the identification of all 89 
re-arrangements. No rearrangements were detected in 
analogous in silico libraries constructed from unrearranged 
IgH loci. 
Identification  of  rearranged  IgH  genes  directly 
from plasma 
Using  the  approach  described  above,  we  first 
attempted to directly identify IgH gene rearrangements 
in DNA purified from plasma in 14 patients in whom no 
tumor tissue was available (clinical characteristics are 
described in Supplementary Table 2). We used an Illumina 
GA2 sequencer to analyze one end of each tag, employing 
one lane per patient. We were thereby able to generate 
2,673,399 to 18,889,095 tags of high quality from the 
14 patients (Table 1). In ten of the samples, we identified 
putative rearrangements (Table 2). We applied the same 
procedure to the plasma DNA of two individuals without 
B-cell neoplasia, and did not identify any rearrangements. 
We then designed primer pairs (Supplementary Table 3) 
that straddled the ten NHL patient rearrangements and used 
them to PCR-amplify DNA from the same plasma samples. 
In eight of the ten cases, we identified PCR products of 
the expected size in the plasma of the appropriate patients 
but not in DNA from normal individuals (Figure 1). The 
PCR fragments were excised from the gel, cloned, and 
sequenced. In each case, the sequence was that predicted 
from the algorithm (with the exception of a single base 
substitution that could have arisen during cloning, whole 
genome amplification or clonal progression).
Identification of rearranged IgH genes in tumors
Though the results described above were encouraging, 
we could not definitively identify rearrangements in 6 of 
the 14 patients. Moreover, the number of IgCap library 
fragments containing sequences corresponding to the 
rearranged gene was generally small, ranging from 1 
to 11 in those patients in which a rearrangement could 
be identified. Plasma DNA is certainly not enriched in 
rearranged fragments, and most IgH gene-containing DNA 
fragments from plasma are undoubtedly derived from 
non-tumor tissue. To improve the sensitivity of IgCap, 
two modifications were made. First and most importantly, 
we used a portion of the original lymphoma, rather than 
Figure 1: PCR amplification of Ig rearrangements in plasma. DNA was purified from either the plasma of patients or from normal 
cells of an unrelated patient (Con). MW, molecular weight markers, size indicated on left in base pairs (bp).
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the plasma, to identify rearrangements, then used plasma 
to determine whether the rearranged IgH gene could be 
detected in the circulation. Second, it became possible 
to sequence both ends of library fragments (“paired-end 
reads”) during the course of this study, and this sequencing 
approach was employed in the remaining experiments.
This modified strategy was applied to DNA isolated 
from the involved lymph nodes of three NHL patients 
(clinical information in Supplementary Table 2). From a 
single lane of an Illumina GAIIx sequencer, we recovered 
20 million tags of high sequence quality, 6-7% of which 
contained homology to V, D, or J regions (Table 1). In each 
of the three patients, IgCap identified two rearrangements 
that were represented by more than 8 tags (Table 2). One 
of the two rearrangements in each patient was presumably 
derived from the maternal allele and the other from 
the paternal allele. Importantly, the number of IgCap 
library fragments containing sequences that bridged the 
rearrangement was more than one in each case, ranging 
from 8 to 36. In two of the six rearrangements, we could 
identify both VD and DJ junctions. In the remaining 4, we 
could only identify the DJ junction. We did not determine 
whether this was due to technical vs. biologic reasons; it 
is well-known that incomplete rearrangements, in which 
D is fused to J but V is not fused to D, occur in neoplastic 
B-cells.[12] 
PCR primers that straddled the six rearrangements 
were used to amplify DNA from the three tumors. In each 
case, PCR products of the expected size were found in 
the tumors of the appropriate patients but not in germ-
line DNA from normal individuals (Figure 2). The 
PCR fragments were excised from the gel, cloned, and 
sequenced. In each case, the sequence was that predicted 
from the IgCap data. 
We next attempted to determine whether the 
rearranged fragments could be identified in the plasma of 
these three patients. In all cases, both rearranged fragments 
were evident and could be detected in as little as 30 ul 
of plasma (Figure 2). The PCR fragments from plasma 
were cloned and found to be identical in sequence to 
those of the corresponding patients’ tumors. The number 
of rearranged fragments was determined by digital PCR 
and found to vary from 30 to 100 fragments per ml of 
plasma. These rearrangements were not detected in DNA 
from circulating cells from the same patients, even when 
the DNA from as many as 1 million circulating cells were 
assessed. . These results are consistent with the idea that 
lymphoma cells are rare in the circulation and that the 
rearranged DNA is released from the tumors in situ rather 
than derived from circulating lymphoma cells.
DIsCussIon 
The results described above show that rearranged 
IgH  genes  can  be  routinely  identified  in  NHL  tumors, 
that the rearranged genes are present in the circulation at 
detectable levels, and that the circulating DNA is more 
abundant than circulating lymphoma cells. Moreover, 
the IgCap approach is powerful enough to identify some 
patients’ rearrangements directly from plasma if no tumor 
biopsy is available. These results set the stage for clinical 
implementation of this type of biomarker to follow the 
course of NHL patients following therapy.
The clonal assessment of rearrangements in 
immunoglobulin or T cell receptor genes has a long history.
[10] Initially, Southern blotting was the gold standard for 
this type of analysis, but required large amounts of high 
quality genomic DNA and lacked the sensitivity required 
for many types of diagnostic assays. Southern blotting 
was replaced with PCR-based assays, which have many 
advantages. Primer sets facilitating multiplex PCR assays 
have been painstakingly designed and shown to detect 
up to 74% DLBCL and 96% FL.[13] Massively parallel 
sequencing of PCR products derived from such primer sets 
has recently been used to identify VDJ rearrangements in 
Ig or T-cell receptor genes. [14-16] The massively parallel 
sequencing approach used herein, in which VDJ genes are 
captured rather than amplified using Ig-specific primers, 
represents  another  means  towards  the  identification 
of clonal rearrangements and their use as biomarkers. 
Though more complex than the direct PCR approach, it 
has the advantage of being less biased; in theory, it should 
detect 100% of rearranged fragments from lymphomatous 
tissues. Additionally, it can be applied to degraded DNA 
Figure 2: PCR amplification of Ig rearrangements in tumors and plasma. Two Ig rearrangements are shown for each patient 
sample. DNA was purified from either from the tumor and plasma of patients or from normal cells of an unrelated patient (Con).  MW, 
molecular weight markers, size indicated on left in base pairs (bp).
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Table 2:   Rearrangements identified in this study
Patient ID Sample type Rearranged Sequence Identified Rearranged 
Genes
Validated by PCR*
Patient 1 Plasma
CTGGGTGGATTCTGAACAGCCCCGAGTCACGGTGGGTATAGTGGGAG
CCGAGGCCTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAGGT
GAGTCCT
IGHD1-1:J5 Yes
Patient 2 Plasma
GCAGACACGGCTGTGTATTACTGTGCGAGACTGGGATCCCCGTATAGC
AGCAGCTGGCCCTACTACTACGGTATGGACGTCTGGGGCCAAGGGAC
CACGGTCACCGTCTC
IGHV4-30-2:J6 Yes
Patient 3 Plasma
CCAGCCCCCAGGGAAGGGACTGGAGTGGATTGGGAGTGTTGATTATT
CTGGGGACACCTTCCATAACCCATCCCTCAAGAGTCGCGTCTCCATATT
AATAGACGCGTCTAAAAACGTTTTCTCTCTGAGGTTGACTTTTGTTACC
GCCGCGGACACGGCCATATATTATTGTGCGGGACATCCTCATAGTACT
GGGTGGTATCAATCTGGGAACTGGTTCGACTCCTGGGGCCAGGGAAC
CCCGGTCACCGTCTCCTCA
IGHV4-4:J5 Yes
Patient 4 Plasma
CCGCGGACACGGCCATCTATTACTGTGCGAGAGATAAAGCAGATAAA
ACATTACGATGGCCCAAGACCTTAAACTGGTTCGACCCCTGGGGCCAC
GGAACCCTGGTCACC
IGHD4-23:J5 Yes
Patient 5 Plasma
CCTGTGGACACAGCCACATATTACTGTGCAGCAGTAGAACTAATTGAG
GCCGGCATGGAACTTGGCTACTGGGGCCCCCGGGAATCCTGGTCAAC
GTCTCCTCAGGTGAGTCCTC
IGHV2-5:J5 Yes
Patient 6 Plasma
TGTCACTGTGGTATTACGATTCTTTGACTGGTTGTTGTCAGCGCGACCC
CTCTTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAGGT
GA
IGHD3-9:J4 Yes
Patient 7 Plasma
CCAGGTGTGGTTATTGTCAGGGGGTGCCAGGCCGTGGTAGAGATGGC
TACAACTACCAACCACGAGGGTACTACTTTGACTACTGGGGCCAGGGA
ACCCTGGTCACC
IGHD5-24:J4 Yes
Patient 8 Plasma CAGGCCGTGGTAGAGATGGCTACAATCAGGATTGCATGGTCGTCGTTT
ACGGGGGGTTTTCTACTGGGGCCAGGGAACCCTGGTCACCGTCTC
IGHD5-24:J4 Yes
Patient 9 Plasma TGTGGTATTACTATGATAGTAGTGTGAGGGGCCAGGGAACCCTGGTC
ACCGTCTCCTCA
IGHD3-22:J5 No
Patient 10 Plasma AACCGAGGACACAGCCGTGTATTACTGTACCACAGGGGCGTACTGGG
GCCAGGGAACCCT
IGHV3-49:J4 No
Patient 11 Plasma - - No
Patient 12 Plasma - - No
Patient 13 Plasma - - No
Patient 14 Plasma - - No
Patient 15 Primary tumor 
TCTGTGACCGCCGCAGACACGGCTGTGTATTTTTGTGCGAGGCAGGTT
GCGACGCAGGGGGCCCCCTTTGACTTCTGGGGCCGGGGAACCCTGAT
CACCGTCTCCTCAGGTGAGTCCT
IGHV4-30-2:J4 Yes
Patient 15 Primary tumor  TGAGGTCTGTGTCACTGTGATATTATGATACTTTGACTGGTTATTTGAG
AAAGTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAGG IGHD3-9:J4 Yes
Patient 16 Primary tumor  GTACGTGCCATGTTAGGATTTTGATCGAGGAGACAGCACCATGGGTAT
GGTTTCACTGGGGCCAGGGCACCCTGGTCACCGTCTCCTCAGGTGA
IGHD3-10:J1 Yes
Patient 16* Primary tumor 
TTCCAGGTGTGGTTATTGTCAGGCGATGTCAGACTGTGGTGGATATAG
TGGCTACGATCCCTCACCTTCTGGGGCCAAGGGACAATGGTCACCGTC
TCTTCAGGTAAGATGGCT
IGHD5-12:J3 Yes
Patient 17 Primary tumor 
GTAGGGACAGGAGGATTTTGTGGGGGCTCGAGTCACTGTGAGCATAT
TGTGGTGGTGATTGCTCCGCTGAATACTTCCACCACTGGGGCCAGGGC
ACCCTGGTCACCGTCTCC
IGHD2-21:J1 Yes
Patient 17 Primary tumor 
TCTTCAAATGAACAACCTGAGAGTCGAGGACACGGCCGTTTATTACTG
TACGAGAGAGACAAATTGTGACTACTGGGGCCAGGGAACCCTGGTCA
CCGTCTCCTCAGGTGA
IGHV3-53:J5 Yes
* The sequence identified through  analysis of the IgCap libraries was identical to that determined from analysis of the PCR 
products used for validation except in Patient 16, in which the sequence differed by a single base (G > A) at position 25.Oncotarget 2011; 2:  178 - 185 183 www.impactjournals.com/oncotarget
samples such as those from paraffin-embedded material 
or plasma. Degraded DNA cannot efficiently be amplified 
with conventionally used primer sets because the product 
size is larger than the size of the DNA.
We used two algorithms to identify rearranged 
Igs. The CTGGGG-based algorithm detects all typical 
rearranged Igs. However, this algorithm can fail to detect 
uncommon Ig rearrangements such as those involving 
only V and D or those involving J region deletions. The 
paired-end algorithm is complementary. It has the capacity 
to pick out any rearrangement involving the IgH locus, 
including Ig rearrangements as well as translocations such 
as  t(8;14)(q24;q32)  in  Burkitt  lymphoma  and  t(11;14)
(q13;q32) in mantle cell lymphoma.
As with all biomarkers, the approach described here 
has limitations. Its major conceptual limitation revolves 
around marker stability: a relapsed lymphoma may have 
undergone clonal divergence so that its rearrangement 
would be undetectable upon PCR with the primers 
used to validate the original tumor.[17] It was therefore 
comforting that in each of the three NHL tumor samples 
evaluated in this study, two distinct rearrangements were 
identified, and both could be identified in the plasma of 
each patient. The availability of two independent markers 
reduces the probability of a false negative during follow-
up. Because the exact sequence of the rearrangement is 
determined with our approach, two sets of primers for 
each rearrangement could be employed, thereby further 
minimizing the potential impact of clonal evolution within 
the rearranged loci. 
Enthusiasm has been growing for risk-adapted 
therapy in the treatment of diffuse large B cell lymphoma. 
Mid cycle FDG PET has been used to guide decisions on 
switching chemotherapy regimens and to select patients for 
high dose consolidation.[18],[19] However, standardized 
interpretation of PET imaging still presents obstacles, as 
recently noted in an ongoing cooperative group trial.[20] 
The plasma-based approach described here represents an 
alternative and perhaps complementary approach to tumor 
assessment. Another important issue to be addressed in 
the future is the sensitivity of the method. In this work, 
we have only evaluated patients with clinically apparent 
disease. It may be more difficult to detect rearranged IgH 
genes in the plasma of patients with minimal residual 
disease following therapy. However, we were encouraged 
by the fact that rearrangements can be detected in as little 
as 30 ul of plasma in the three patients whose levels were 
quantified. This suggests that disease burdens amounting 
to only 1% of those of the studied patients could be readily 
detected in 3 ml of plasma, assuming the relationship 
between disease burden and plasma DNA is linear. 
Do the rearrangements detected with IgCap 
represent those occurring in the tumor cells? In the 
three cases in which the rearrangements were identified 
in the tumor, there can be little doubt of this, as the 
number of IgCap library fragments corresponding to the 
major rearrangement outnumbered any other putative 
rearrangements in the sample by more than a hundred-fold. 
In the cases in which only plasma DNA was available, it 
is theoretically possible that the identified rearrangements 
arose from normal B-cells. Two observations argue 
against this possibility. First, we have attempted the IgCap 
strategy on two samples of plasma from patients without 
B-cell neoplasms and have not identified any rearranged 
fragments in IgCap libraries from them. Second, there 
were two patients in whom a plasma sample taken during 
complete remission was available, and the rearrangements 
could not be identified in these either (through PCR with 
the  rearrangement-specific  primers).  Regardless,  it  is 
clearly optimal to identify the rearranged biomarker by 
employing the IgCap strategy on DNA from lymphomas, 
rather than from plasma, whenever the former is available. 
The biomarker can then be easily applied to plasma using 
PCR, as described above.
In sum, IgCap is an advanced, personalized medicine 
approach that provides exciting research opportunities 
and offers the potential for clinical application. The 
basic idea of IgCap could be applied to other diseases, 
including those with an autoimmune or allergic basis, 
to define the number and nature of Ig rearrangements in 
clinical samples. With minor modifications, it might also 
be applied to the evaluation of T-cells.
MateRIals anD MetHoDs
samples
All samples in this study were obtained from patients 
under an Institutional Review Board protocol. 
Dna purification
DNA was extracted from 1000 µL of plasma with 
a QIAamp Circulating Nucleic Acid kit following the 
manufacturer’s  instructions.  (QIAGEN;  Valencia,  CA). 
DNA was extracted from tumor tissues and normal cells 
using a Qiagen AllPrep kit following the manufacturer’s 
protocol.
Illumina library preparation
Tumor genomic DNA libraries were prepared 
following Illumina’s (Illumina, San Diego, CA) protocol 
with the following modifications. (1) Three micrograms 
(µg) of genomic DNA in 100 microliter (µl) of TE was 
fragmented in a Covaris sonicator (Covaris, Woburn, 
MA) to a size of 100-500bp. DNA was purified with a 
PCR  purification  kit  (Cat  #  28104,  Qiagen,  Valencia, 
CA) and eluted in 35µl of elution buffer included in the Oncotarget 2011; 2:  178 - 185 184 www.impactjournals.com/oncotarget
kit. (2) Purified, fragmented DNA was mixed with 40 µl 
of H2O, 10 µl of 10xT4 ligase buffer with 10mM ATP, 
4 µl of 10mM dNTP, 5 µl of T4 DNA polymerase, 1 µl 
of Klenow Polymerase, and 5 µl of T4 polynucleotide 
Kinase. All reagents used for this step and those described 
below were from New England Biolabs (NEB, Ipswich, 
MA)  unless  otherwise  specified.  The  100µl  end-repair 
mixture was incubated at 20oC for 30 min, purified by 
a PCR purification kit (Cat # 28104, Qiagen) and eluted 
with 32µl of elution buffer (EB). (3) To A-tail, all 32 µl 
of end-repaired DNA was mixed with 5 µl of 10xBuffer 
(NEB buffer 2), 10 µl of 1mM dATP and 3 µl of Klenow 
(exo-). The 50 µl mixture was incubated at 37oC for 30 
min  before  DNA  was  purified  with  a  MinElute  PCR 
purification kit (Cat # 28004, Qiagen). Purified DNA was 
eluted with 12.5 µl of 70oC EB. (4) For adaptor ligation, 
10 µl of A-tailed DNA was mixed with 10 µl of adapters 
(Illumina), 25 µl of 2x Rapid Lgase buffer and 5 µl of 
Rapid Ligase. The ligation mixture was incubated at room 
temperature (RT) for 15 min. (5) To purify adapter- ligated 
DNA, 50 µl of ligation mixture from step (4) was mixed 
with 200 µl of NT buffer from NucleoSpin Extract II kit 
(cat# 636972, Clontech, Mountain View, CA) and loaded 
into a NucleoSpin column. The column was centrifuged at 
13,000 g in a desktop centrifuge for 1 min, washed once 
with 600 µl of wash buffer (NT3 from Clontech), and 
centrifuged again for 2 min to dry completely. DNA was 
eluted in 50µl elution buffer included in the kit. (6) To 
obtain an amplified library, ten PCRs of 25 µl each were 
set up, each including 12 µl of H2O, 5 µl of 5 x Phusion 
HF buffer, 0.5 µl of 10 mM dNTP, 1.25 µl of DMSO, 0.5 
µl of Illumina PE primer #1, 0.5 µl of Illumina PE primer 
#2, 0.25 µl of Hotstart Phusion polymerase, and 5 µl of 
the DNA from step (5). The PCR program used was: 98oC 
1 minute; 6 cycles of 98oC for 20 seconds, 65oC for 30 
seconds, 72oC for 30 seconds; and 72oC for 5 min. To 
purify the PCR product, 250 µl PCR mixture (from the 
ten PCR reactions) was mixed with 500 µl NT buffer from 
NucleoSpin  Extract  II  kit  and  purified  as  described  in 
step (5). Library DNA was eluted with elution buffer pre-
heated to 70oC and the DNA concentration was estimated 
by absorption at 260 nm.
IgCap capture 
The targeted capture region included V-gene exons 
plus the first 36 bp of the downstream introns, six J-gene 
exons plus the first 36 bp of the upstream introns, and 
all the D-gene exons. We obtained these regions through 
PCR of normal genomic DNA using the primers described 
in Supplementary Table 4 or custom synthesized probes 
and then used a strategy based on that described in [11] 
to  capture  the  IgH  genome.  PCR  using  these  primers 
was  performed  using  the  reaction  conditions  specified 
previously.[21]
Confirmation  of  IgH  rearrangements  in  tumor 
and plasma samples
The  full  V-D-J  or  D-J  joint  region  sequence  and 
40 bp from either side of the joint were used for primer 
design.  The  PCR  mixture  (50  μl)  contained  various 
amounts of template DNA, 0.2 μM of forward-reverse 
primer mixture, 2.5 mM of MgCl2, 100 μM of dNTPs, 
and 0.5 units of Invitrogen Taq polymerase. PCR was 
performed as follows: 96°C for 4 min; 45 cycles of 96°C 
for 10 s, 59°C for 10 s , and 72°C for 30 s. The primers 
used for PCR are listed in Supplementary table 3. PCR 
products were gel purified with QIAquick Gel Extraction 
Kit (QIAGEN;  Valencia,  CA) and cloned with a TA 
clone kit (Promega, Madison, WI, USA) according to the 
manufacture’s protocols. Plasmid DNA was evaluated 
by Sanger sequencing. Digital PCR was performed as 
described before.[22] 
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